Expert NetworkExpert InterviewNVS

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo for BRAF V600E mutated low-grade glioma with a pediatric neuro-oncologist.

Executed on:Mar 27, 2023 10:00 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: UT Southwestern
  • Professor of Pediatric Hematology and Oncology & Medical Director of Pediatric neuro-oncology at Children's Health at University of Texas Southwestern.
  • Manages 15 patients a week with glioma and 4 patients for BRAF V600E-mutated low-grade glioma.
  • Research and clinical interests include the development of new therapies for children with brain tumors and cancer survivorship.

Interview Goal

Digging in to the findings from the Phase 2 Study CDRB436G2201 trial which lead to the recent FDA approval of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) combo for BRAF V600E mutated low-grade glioma in kids aged 1 year and up.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.